PTPN11 and cancer: Development of the tyrosine phosphatase SHP2 (PTPN11) inhibitors has been the focus of considerable research efforts in light of their diverse role in cancer and RASopathies disorders (Butterworth et al., 2014; Garcia Fortanet et al., 2016; Yu and Zhang, 2018).